Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Regorafenib · 1 trial · 1 indication
time from randomization to the date of death due to any cause. For patients still alive at the time of analysis, the OS time will be censored on the last date the patients were known to be alive.
| Arm | Type | Description |
|---|---|---|
| Panitumumab followed by Regorafenib | ACTIVE_COMPARATOR | - |
| Regorafenib followed by Panitumumab | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Regorafenib | DRUG | regorafenib administered until progression, unacceptable toxicity or patient's refusal followed after progression by panitumumab until further progression, unacceptable toxicity or patient's refusal in RAS and BRAF wt mCRC patients with the following characteristics: 1. previous treatment with, or not considered candidates for, fluoropyrimidine, oxaliplatin, irinotecan and anti-angiogenic agent (bevacizumab or aflibercept); 2. RECIST response or stable disease lasting at least 6 months to a previous first-line anti-EGFR-based treatment; 3. RAS and BRAF wt ct-DNA at the time of screening. |
| Panitumumab | DRUG | panitumumab administered until progression, unacceptable toxicity or patient's refusal followed after progression by regorafenib until further progression, unacceptable toxicity or patient's refusal in RAS and BRAF wt mCRC patients with the following characteristics: 1. previous treatment with, or not considered candidates for, fluoropyrimidine, oxaliplatin, irinotecan and anti-angiogenic agent (bevacizumab or aflibercept); 2. RECIST response or stable disease lasting at least 6 months to a previous first-line anti-EGFR-based treatment; 3. RAS and BRAF wt ct-DNA at the time of screening. |
Inclusion Criteria: * Age ≥ 18 years. * Written informed consent to molecular analyses. * Histologically proven diagnosis of CRC. * At least one measurable lesion according to RECIST1.1 * ECOG PS ≤ 1. * mCRC previously treated for metastatic disease with, or not considered candidates for, fluoropyr...
Top 20 of 76 competitors
Regorafenib is an investigational small molecule being studied for the treatment of colorectal cancer. It is currently in Phase 2 clinical development, with an active trial evaluating its use in patients with this disease. The drug is being developed by Amgen Inc.
Regorafenib is a kinase inhibitor that targets DDR2, EPHA2, FGFR2, MAPK11, PDGFRB, and PDGFRA. By inhibiting these molecular targets, the drug is being investigated for its potential role in treating colorectal cancer.
Regorafenib is being developed by Amgen Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol AMGN. The drug is currently in Phase 2 clinical trials for colorectal cancer.
Regorafenib is in Phase 2 clinical development for colorectal cancer. It is an investigational drug and has not been approved by regulatory authorities. The ongoing Phase 2 trial is active but not recruiting participants.
Regorafenib is being studied in the Phase 2 clinical trial NCT04787341, titled 'PAnitumumab REchallenge Followed by REgorafenib Versus the Reverse Sequence.' This randomized, active-controlled trial is enrolling 214 participants with colorectal cancer in Italy.
Regorafenib is a distinct small molecule drug developed by Amgen Inc. It is not known by any other names in the available clinical trial information. The drug is being evaluated specifically for its effects in colorectal cancer.